HCAT250117P2500
- 0.01
- 0.000.00%
Health Catalyst Newsroom
Health Catalyst Is Maintained at Buy by Canaccord Genuity
Health Catalyst Price Target Cut to $10.00/Share From $11.00 by Canaccord Genuity
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $10
Wells Fargo Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $10
Wells Fargo Remains a Buy on Health Catalyst (HCAT)
Stifel Downgrades Health Catalyst(HCAT.US) to Hold Rating, Maintains Target Price $10
Stifel Nicolaus Remains a Hold on Health Catalyst (HCAT)
Evercore Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $7
Evercore ISI Reaffirms Their Buy Rating on Health Catalyst (HCAT)
Health Catalyst Analyst Ratings
RBC Capital Maintains Health Catalyst(HCAT.US) With Hold Rating, Cuts Target Price to $7
RBC Cuts Price Target on Health Catalyst to $7 From $9, Keeps Sector Perform Rating
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Health Catalyst (HCAT) and Amicus (FOLD)
Health Catalyst Is Maintained at Buy by Citigroup
Health Catalyst Analyst Ratings
Citi Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $10
RBC Capital Maintains Health Catalyst(HCAT.US) With Hold Rating, Maintains Target Price $9
RBC Capital Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Health Catalyst Raised to Overweight From Sector Weight by Keybanc
KeyBanc Upgrades Health Catalyst(HCAT.US) to Buy Rating, Announces Target Price $9